The Europe Rare Diseases Treatment Market would witness market growth of 12% CAGR during the forecast period (2022-2028).
Manufacturers of the new drugs benefit from tax breaks, quick approvals, and other research grants, allowing for much more innovation. Product development can lead to technological products and medical or pharmaceutical innovations that can be utilized to expand into new markets. The general public is conscious of such rare diseases, and this awareness is growing as a result of the government's efforts.
Adding to this scenario, cost recovery strategies in developed nations are driving up the demand for rare disease treatments. Ignorance of rare diseases can be more expensive than research aimed at increasing knowledge. Rare genetic diseases frequently affect patients at a young age and reduce life expectancy, so affected individuals may need health care for the rest of their lives.
The adoption of more advanced home healthcare equipment, as well as the launch of innovative value-based payment and service models, have created a profitable investment opportunity in U.K. healthcare. As the region's healthcare industry expands, the regional market players are contributing heavily in the development of advanced rare diseases treatment in the region. With R&D corporation tax relief, the UK encourages investment as well as rewards innovation in the healthcare life sciences & technology sector. As a result of this, vendors are increasingly investing in the Europe region.
The Germany market dominated the Europe Rare Diseases Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16,772 million by 2028. The UK market would experience a CAGR of 11.1% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 12.9% during (2022 - 2028).
Based on Distribution Channel, the market is segmented into Specialty Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable, Oral, and Others. Based on Therapeutic Area, the market is segmented into Cancer, Cardiovascular Conditions, Infectious Diseases, Musculoskeletal Conditions, Endocrine Disorders, Metabolic Disorders, Hematologic Disorders, Neurological Conditions, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Rare Diseases Treatment Market will Hit $255.4 Billion by 2028, at a CAGR of 12.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AbbVie, Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Novartis AG, Merck Group, Bristol Myers Squibb Company, Pfizer, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited and PTC Therapeutics, Inc.
By Drug Type
By Distribution Channel
By Route of Administration
By Therapeutic Area
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.